Galecto is committed to developing novel therapeutics for cancer and severe liver diseases with a high unmet medical need.
Fibrosis is a severe scarring process that occurs in many chronic diseases of the liver, kidneys, heart, joints and eye. It can severely disrupt organ functions, leading to irreversible organ failure, and the need for transplantation, and can also be fatal in some cases.
Galecto’s small molecule pipeline targets a key protein involved in the fibrotic process, galectin-3.
Galecto, Inc. develops small molecules for the treatment of cancer and severe liver diseases. The company is built on nearly 15 years of research centering on the role of galectin-3 and the use of modulators of these proteins to treat cancer and severe liver diseases. These assets, combined with BRM-1420, a novel dual ENL-YEATS / FLT3 inhibitor, provide Galecto with a unique therapeutic platform.